AILERON THERAPEUTICS
Biotechnology, 490 Arsenal Way, Watertown, Massachusetts, 02472, 11-50 Employees
Phone Number: +16*********
Who is AILERON THERAPEUTICS
Aileron is a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives. ALRN-6924,...
Read More
-
Headquarters: 490 Arsenal Way, Watertown, Massachusetts, 02472
-
Date Founded: 2005
-
Employees: 11-50
-
Revenue: 5 Million to 10 Million
-
Active Tech Stack: See technologies
-
CEO: Manuel Aivado
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from AILERON THERAPEUTICS
View Employees
Aileron Therapeutics Org Chart and Mapping
Similar Companies to Aileron Therapeutics
Amulet
-
11-50
-
$ 5 Million to 10 Million
Biomiga
-
11-50
-
$ 5 Million to 10 Million
Dna Software
-
11-50
-
$ 5 Million to 10 Million
Aileron Therapeutics Activity Score
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Aileron Therapeutics
Answer: Aileron Therapeutics's headquarters are located at 490 Arsenal Way, Watertown, Massachusetts, 02472
Answer: Aileron Therapeutics's phone number is +16*********
Answer: Aileron Therapeutics's official website is https://aileronrx.com
Answer: Aileron Therapeutics's revenue is 5 Million to 10 Million
Answer: Aileron Therapeutics's SIC: 2834
Answer: Aileron Therapeutics's NAICS: 325412
Answer: Aileron Therapeutics has 11-50 employees
Answer: Aileron Therapeutics is in BIOTECHNOLOGY
Answer: Aileron Therapeutics top competitors include: Dyve Biosciences, Pbs Biotech, Biomiga, Dna Software, Amulet, Syndevrx, Gain Therapeutics, In8Bio, Marin Biologic Laboratories, Lynx Biosciences
Answer: Aileron Therapeutics contact info: Phone number: +16********* Website: https://aileronrx.com
Answer: Aileron is a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy. Our vision is to bring chemoprotection to patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of type of cancer or chemotherapy. Visit us at aileronrx.com to learn more.
Answer:
Premium Sales Data for Prospecting
- Sales data across over 200M records
- Up-to-date records (less decayed data)
- Accurate Email Lists (real-world tested)
- Powerful search engine and intuitive interface
View Employees
Aileron Therapeutics Activity Score
Sign in to CIENCE GO Data to uncover contact details
Free credits every month